9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
The DOI matches its Crossref record; 104 of the 106 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc22-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc22-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While generally well tolerated, an increased risk of HHF was found with saxagliptin, which is re fl ected in its label, and there have been rare reports of arthralgia and hypersensitivity reactions with the DPP-4i class (16).”
In the citing paper
“Current treatment protocols propose considering weight impact when choosing diabetes treatment strategies, and GLP-1RAs have shown a notably positive therapeutic profile for overweight or obese individuals with T2DM. 78”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [78]
In the citing paper
“Currently, these guidelines recommend SGLT2is and GLP-1RAs as the preferred therapy among individuals with type 2 diabetes and comorbid ASCVD or HF, and SGLT2is among those with comorbid CKD [8, 9].”
In the citing paper
“The ADA/ EASD statement recommends that patients with T2D who have established ASCVD, CKD, or clinical heart failure be treated with an SGLT2i (or GLP-1 RA) with proven cardiovascular bene fi t as part of a glucose-lowering regimen independent of HbA1c, but with consideration of patient-speci fi c factors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [147]
In the citing paper
“Based on evidence from large cardiovascular outcomes trials, the latest professional society guidelines continue to recommend sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD).1,2”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“Metformin is effective and safe, is inexpensive, and may reduce risk of cardiovascular events and death (45).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · cited 1×
“The ADA/EASD consensus report “Management of Hyperglycemia in Type 2 Diabetes, 2018” and the 2019 update (43,44) recommend a patient-centered approach to choosing appropriate pharmacologic treatment of blood glucose.”
BackgroundRiddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M. B., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 965
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
Research works printed but not linked: 2
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Vaz, 2018, Effectiveness and safety of carbohydrate counting in the management of adult patients with type 1 diabetes mellitus: a systematic review and meta-analysis, Arch Endocrinol Metab, 62, 337
Cited by
Items 201–300 of 1,000
Tang, Y., Zhang, L., Zeng, Y., Wang, X., & Zhang, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1016639 · Cited by 38
Wanchaitanawong, W., Thinrungroj, N., Chattipakorn, S. C., Chattipakorn, N., & Shinlapawittayatorn, K. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109230 · Cited by 34
Wilson, J. M., Farley, K. X., Broida, S. E., Bradbury, T. L., & Guild, G. N. (2021) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.20.01535 · Cited by 36
Tanaka, A., Sata, M., Okada, Y., Teragawa, H., Eguchi, K., Shimabukuro, M., Taguchi, I., Matsunaga, K., Kanzaki, Y., Yoshida, H., et al. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac059 · Cited by 34
King, A., & Miller, E. M. (2022) · Clinical Diabetes · doi:10.2337/cd22-0027 · Cited by 34
Natural products from plants targeting key enzymes for the future development of antidiabetic agents
Mata, R., Flores‐Bocanegra, L., Ovalle‐Magallanes, B., & Figueroa, M. (2023) · Natural Product Reports · doi:10.1039/d3np00007a · Cited by 37
Gonzalez, J., Bates, B. A., Setoguchi, S., Gerhard, T., & Dave, C. V. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01784-w · Cited by 32
Xie, Y., Huan, M., Sang, J.-J., Luo, S.-S., Kong, X., Xie, Z., Zheng, S.-H., Wei, Q., & Wu, Y. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/2286598 · Cited by 36
Ferreira, J. P., Sharma, A., Vasques‐Nóvoa, F., Angélico‐Gonçalves, A., Leite, A. R., Borges‐Canha, M., Carvalho, D. M., Packer, M., Zannad, F. M., Leite-Moreira, A. F., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2660 · Cited by 32
“Difference between albiglutide and placebo: (1) heart rate: No HF: 8 months +1.”
BackgroundNapoli, R., Berra, C., Catarig, A., Di Loreto, C., Donatiello, E., Berentzen, T. L., Pitocco, D., & Giorgino, F. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15020 · Cited by 32
“However, discontinuation of DPP-4i treatment is recommended when adding GLP-1RA, because of overlapping mechanisms of action.(34) DPP-4is block DPP-4 from degrading GLP-1, increasing endogenous levels of GLP-1, whereas GLP-1RAs mimic the stimulatory effects of GLP-1.”
BackgroundMethodPurnell, J. Q. (2023) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2023.03.001 · Cited by 37
Lyu, Y. S., Oh, S. K., Kim, J. H., Kim, S. Y., & Jeong, M. H. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01914-4 · Cited by 36
“Based on these results, the 2022 American Diabetes Association guidelines have recommended the use of SGLT2i in patients diagnosed with type 2 DM and who have a history of, or are at high risk for, ASCVDs and HF [8].”
BackgroundAssociation of SGLT-2 inhibitors with bacterial urinary tract infection in type 2 diabetes
Tanrıverdi, M., Baştemir, M., Demirbakan, H., Ünalan, A., Türkmen, M., & Tanrıverdi, G. Ö. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01464-6 · Cited by 43
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management
Taha, M. B., Yahya, T., Satish, P., Laird, R., Agatston, A. S., Cainzos-Achirica, M., Patel, K. V., & Nasir, K. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01041-7 · Cited by 31
Liu, Z., Yu, S., Jin, X., Sheng, L., Rouzi, M. R. Y., Gao, J., Lü, J., & Lei, T. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s559919 · Cited by 35
Cavaiola, T. S., Kiriakov, Y., & Reid, T. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.11.015 · Cited by 33
Htoo, P. T., Tesfaye, H., Schneeweiß, S., Wexler, D. J., Everett, B. M., Glynn, R. J., Kim, S. C., Najafzadeh, M., Koeneman, L., FARSANI, S. F. F., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.37606 · Cited by 33
Five-year Weight Loss Maintenance With Obesity Pharmacotherapy
Weintraub, M. A., D’Angelo, D., Tchang, B. G., Sahagun, A., Andre, C., Aronne, L. J., & Shukla, A. P. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad100 · Cited by 33
Kiyosue, A., Dunn, J. P., Cui, X., Hickey, A., Hirase, T., Imaoka, T., & Heine, R. J. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14952 · Cited by 30
Dani, S. S., Makwana, B., Khadke, S., Kumar, A., Jhund, P., Nasir, K., Sattar, N., Al-Kindi, S., Fonarow, G., Butler, J., et al. (2025) · JACC: Advances · doi:10.1016/j.jacadv.2025.101740 · Cited by 30
Krisanapan, P., Sanpawithayakul, K., Pattharanitima, P., Thongprayoon, C., Miao, J., Mao, M. A., Suppadungsuk, S., Tangpanithandee, S., Craici, I. M., & Cheungpasitporn, W. (2024) · Diseases · doi:10.3390/diseases12010014 · Cited by 36
“The American Diabetes Association (ADA) also recommends these agents as initial therapy for T2DM patients with CKD, regardless of albuminuria levels [7].”
BackgroundLEVIN, P. A., Hoogwerf, B. J., Snell‐Bergeon, J. K., Vigers, T., Pyle, L. L., & Bromberger, L. A. (2020) · Endocrine Practice · doi:10.1016/j.eprac.2020.10.004 · Cited by 32
Pavlović, K., Jakovljevic, N. K., Isakovic, A. M., Ivanovic, T., Marković, I., & Lalic, N. M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.930308 · Cited by 31
Zhang, Y., Wang, R. L., Yang, Y., ning, M., Zhi, Z., Tan, Y., Lin, D., Li, Y., Lu, W., Wu, C., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154423 · Cited by 30
Sahay, R. K., Giri, R., Shembalkar, J., Gupta, S. K., Mohan, B., Kurmi, P. H., Kumar, S., Sawardekar, V. M., Mishra, A., Murthy, L. S., et al. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02523-z · Cited by 30
Pharmacological Approaches Using Diabetic Drugs Repurposed for Alzheimer’s Disease
Adem, M. A., Decourt, B., & Sabbagh, M. N. (2024) · Biomedicines · doi:10.3390/biomedicines12010099 · Cited by 34
“These drugs have been approved for use in a multitude of diseases, such as TD2M [149], decreasing the risk of major cardiovascular events in patients with T2DM and established cardiovascular disease [150], decreasing the risk of eGFR decline and the hospitalization of patients with chronic kidney…”
BackgroundPathophysiology and Advances in the Therapy of Cardiomyopathy in Patients with Diabetes Mellitus
Graczyk, P., Dach, A., Dyrka, K., & Pawlik, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25095027 · Cited by 32
Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells
Lu, R., Yang, J., Wei, R., Ke, J., Tian, Q., Yu, F., Liu, J., Zhang, J., & Hong, T. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198938 · Cited by 30
Gomez-Peralta, F., & Abreu, C. (2019) · Drug Design, Development and Therapy · doi:10.2147/dddt.s165372 · Cited by 27
Kelly, M., Lewis, J., Rao, H., Carter, J., Portillo, I., & Beuttler, R. (2022) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2737 · Cited by 29
McAuley, S. A., de Bock, M. I., Sundararajan, V., Lee, M. H., Paldus, B., Ambler, G. R., Bach, L. A., Burt, M. G., Cameron, F. J., Clarke, P., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020274 · Cited by 29
Monnier, L., Colette, C., Schlienger, J.-L., Bauduceau, B., & Owens, D. R. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.01.007 · Cited by 30
Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering
Neuen, B. L., Cherney, D. Z. I., Jardine, M., & Perkovic, V. (2019) · Canadian Medical Association Journal · doi:10.1503/cmaj.190047 · Cited by 32
Nutraceuticals use and type 2 diabetes mellitus
Le, Y., Wang, B., & Xue, M. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.12.004 · Cited by 30
Diaconu, C.-T., & Guja, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175144 · Cited by 33
Clinical pharmacology of antidiabetic drugs: What can be expected of their use?
Scheen, A. J. (2022) · La Presse Médicale · doi:10.1016/j.lpm.2022.104158 · Cited by 29
Yang, Y., Miao, C., Wang, Y., He, J., & Bo, Y. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3830 · Cited by 31
Incretin-based therapy and pancreatitis: accumulating evidence and unresolved questions
Saisho, Y. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.02.24 · Cited by 31
Berra, C. C., Rossi, M. C., Mirani, M., Ceccarelli Ceccarelli, D., Romano, C., Sassi, L., Peretti, E., Favacchio, G., Pastore, I., Folini, L., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1099451 · Cited by 28
Kimura, Y., Jo, T., Inoue, N., Suzukawa, M., Hashimoto, Y., Kumazawa, R., Ishimaru, M., Matsui, H., Yokoyama, A., Tanaka, G., et al. (2024) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2024.05.002 · Cited by 29
Chang, K.-C., Shao, S.-C., Kuo, S., Yang, C.-Y., Chen, H.-Y., Chan, Y.-Y., & Ou, H.-T. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01148-8 · Cited by 28
Zhao, Y., Li, M., Wang, Y., Geng, R., Fang, J., Liu, Q., Kang, S., Zeng, W., Huang, K., & Tong, T. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2045895 · Cited by 31
Metformin as a booster of cancer immunotherapy
Panaampon, J., Zhou, Y., & Saengboonmee, C. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110528 · Cited by 31
Qu, C., Tan, X., Hu, Q., Tang, J., Wang, Y., He, C., He, Z., Li, B., Fu, X., & Du, Q. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26863 · Cited by 32
Szmuilowicz, E. D., & Aleppo, G. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2110507 · Cited by 27
Comparative Effectiveness of Individual Sodium-Glucose Cotransporter 2 Inhibitors
Shin, H., Paik, J. M., Everett, B. M., DiCesare, E., ALIX, C., Glynn, R. J., Wexler, D. J., & Patorno, E. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.7357 · Cited by 33
Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs
Alfayez, O. M., Yami, M. S. A., Alshibani, M., Fallatah, S., Alkhushaym, N., Alsheikh, R., & Alkhatib, N. S. (2019) · Primary care diabetes · doi:10.1016/j.pcd.2019.01.003 · Cited by 28
Hwang, J. G., Lee, S., Huh, W., Han, J., Oh, J., Jang, I., & Yu, K. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15348 · Cited by 29
Singh, L. G., Ntelis, S., Siddiqui, T., Seliger, S. L., Sorkin, J. D., & Spanakis, E. K. (2023) · Diabetes Care · doi:10.2337/dc23-1129 · Cited by 28
Green, J. B., Everett, B. M., Ghosh, A., Younes, N., Krause-Steinrauf, H. J., Barzilay, J. I., Desouza, C. V., Inzucchi, S. E., Pokharel, Y., Schade, D. S., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.066604 · Cited by 30
Llombart‐Cussac, A., Pérez-García, J. M., Borrego, M. R., Tolosa, P., Blanch, S., Fernández-Ortega, A., Urruticoechea, A., Blancas, I., Saura, C., Rojas, B., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102520 · Cited by 30
Mariye, T., Girmay, A., Wube, T. B., Atalay, H. T., Teklay, G., Baraki, Z., Gerensea, H., Teklu, T., & Bezabeh, G. (2019) · Pan African Medical Journal · doi:10.11604/pamj.2019.33.309.17547 · Cited by 32
Mishriky, B. M., Cummings, D. M., Powell, J. R., Sewell, K. A., & Tanenberg, R. J. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.09.002 · Cited by 27
Jordan, K., Fawsitt, C. G., Carty, P. G., Clyne, B., Teljeur, C., Harrington, P., & Ryan, M. (2022) · The European Journal of Health Economics · doi:10.1007/s10198-022-01494-2 · Cited by 26
“However, an important limitation of the underlying clinical effectiveness data is that many RCTs and observational studies were undertaken prior to the widespread use of a number of new, effective anti-hyperglycaemic medication classes with additional benefits in terms of weight loss and cardiovascular risk factor con…”
BackgroundRole of Intermittent Fasting in the Management of Prediabetes and Type 2 Diabetes Mellitus
Ojo, T. K., Joshua, O. O., Ogedegbe, O. J., Oluwole, O., Ayoade, A. O., & Jesuyajolu, D. A. (2022) · Cureus · doi:10.7759/cureus.28800 · Cited by 31
Emulating the GRADE trial using real world data: retrospective comparative effectiveness study
Deng, Y., Polley, E. C., Wallach, J. D., Dhruva, S. S., Herrin, J. S., Quinto, K., Gandotra, C., Crown, W. H., Noseworthy, P. A., Yao, X., et al. (2022) · BMJ · doi:10.1136/bmj-2022-070717 · Cited by 28
Scheen, A. J. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101405 · Cited by 26
Gravel, C. A., Krewski, D. R., Mattison, D. R., Momoli, F., & Douros, A. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15711 · Cited by 26
Khera, R., Dhingra, L. S., Aminorroaya, A., Li, K., Zhou, J. J., Arshad, F., Blacketer, C., Bowring, M. G., Bu, F., Cook, M. B., et al. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2023-000651 · Cited by 32
“3 Consequently, international clinical practice guidelines increasingly recognize the evolution of second line drugs as a treatment option for diabetes, 6 favoring the use of GLP-1 RAs in over a third and SGLT2is in over half of all patients with type 2 diabetes mellitus.”
Hung, C., Liu, J., Cheng, C., Chung, C., Chiang, C., Chien, W., & Wang, W. (2019) · The Journal of Dermatology · doi:10.1111/1346-8138.15195 · Cited by 26
Abdrabou Abouelmagd, A., Abdelrehim, A. M., Bashir, M. N., Abdelsalam, F., Marey, A., Tanas, Y., Abuklish, D. M., & Belal, M. M. (2025) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2025.2456441 · Cited by 25
Natale, P., Green, S. C., Tunnicliffe, D. J., Pellegrino, G., Toyama, T., & Strippoli, G. F. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015849.pub2 · Cited by 40
Mosslemi, M., Park, H. L., McLaren, C. E., & Wong, N. D. (2020) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000189 · Cited by 25
Lewis, G. F., & Hegele, R. A. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00284-9 · Cited by 27
Kyriakidou, A., Kyriazou, A. V., Koufakis, T., Vasilopoulos, Y., Grammatiki, M., Tsekmekidou, X., Avramidis, I., Baltagiannis, S., Goulis, D. G., Zebekakis, P. E., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030424 · Cited by 28
Is Time-Restricted Eating Safe in the Treatment of Type 2 Diabetes?—A Review of Intervention Studies
Uldal, S., Clemmensen, K. K. B., Persson, F., Færch, K., & Quist, J. S. (2022) · Nutrients · doi:10.3390/nu14112299 · Cited by 28
Korayem, G. B., Alshaya, O. A., Alghamdi, A. A., ALANAZI, S., Almutib, R. T., Alsaileek, M., Alrashidi, A., Aldosari, N., Sheraim, N. B., Yami, M. S. A., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1031306 · Cited by 26
Lin, Y., Mok, M., Harrison, J., Battistella, M., Farrell, A., Leung, M., & Cheung, C. (2022) · Transplantation Reviews · doi:10.1016/j.trre.2022.100729 · Cited by 26
Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes?
Albert, S. G., Wood, E. M., & Ahir, V. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102696 · Cited by 26
Machine Learning Approach to Drug Treatment Strategy for Diabetes Care
Fujihara, K., & Sone, H. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0349 · Cited by 28
Alguwaihes, A. M., Alhozali, A. M., Yahia, M., Abdel-Nabi, T., Hatahet, M. H., Albalkhi, N., & Sifri, S. A. (2023) · Saudi Medical Journal · doi:10.15537/smj.2023.44.1.20220402 · Cited by 28
Park, J., Kim, G., Kim, B., Han, K., Kwon, S. Y., Park, S., Lee, Y., Jin, S., & Kim, J. H. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0346 · Cited by 26
Mohammedi, K., Belhatem, N., Berentzen, T. L., Catarig, A., & Potier, L. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15045 · Cited by 25
Ying, W., Song, M., Wen, C. Y., Kaizu, X., Wu, M., & Liming, L. (2023) · Redox Report · doi:10.1080/13510002.2023.2218684 · Cited by 26
Model predictive control for dose guidance in long acting insulin treatment of type 2 diabetes
Aradóttir, T. B., Boiroux, D., Bengtsson, H. L., Kildegaard, J., Jensen, M. L., Jørgensen, J. B., & Poulsen, N. K. (2019) · IFAC Journal of Systems and Control · doi:10.1016/j.ifacsc.2019.100067 · Cited by 26
Yoosuf, B. T., Muhammed Favas, K. T., Spoorthy, D. P., Saini, A., Garg, P., Medenica, S., Dutta, P. R., & Bansal, D. (2025) · Endocrine · doi:10.1007/s12020-025-04393-7 · Cited by 25
“Speci fi cally, few clinical guidelines recommend SGLT-2is, such as “ canagli fl ozin, empagli-fl ozin, dapagli fl ozin, and ertugli fl ozin ” , as preferred second-line treatment choices for patients with cardiovascular disease in whom glycaemic targets are not met with mono-therapy [9 – 11].”
Kugler, A. J., & Thiman, M. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s134960 · Cited by 27
Liao, J., Kang, A., Xia, C., Young, T. K., Tanna, G. L. D., Arnott, C. G., Pollock, C. A., Krishnan, A. V., Agarwal, R., Bakris, G. L., et al. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101331 · Cited by 25
Kushner, P. R., Cavender, M. A., & Mende, C. W. (2022) · Clinical Diabetes · doi:10.2337/cd21-0119 · Cited by 29
Managing thrombotic risk in patients with diabetes
Camm, A. J., Sabbour, H. M., Schnell, O., Summaria, F., & Verma, A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01581-x · Cited by 28
Guan, R., Yang, Q., Yang, X., Du, W., Li, X., & Ma, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.998816 · Cited by 27
“Glucagon-like peptide one receptor agonists (GLP1-RAs) have demonstrated remarkable glycemic control, favorableweight-loss, and cardiorenal outcomes, thus are recommended as first-line injectable therapy for T2DM patients by current guidelines (Draznin et al., 2022).”
BackgroundLim, J., Hwang, I., Choi, H., Yoon, Y. E., & Cho, G. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269414 · Cited by 26
Clinical implications and guidelines for CKD in type 2 diabetes
Zhang, R. M., Persson, F., McGill, J. B., & Rossing, P. R. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac285 · Cited by 27
Devineni, D., Akbarpour, M., Gong, Y., & Wong, N. D. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07403-2 · Cited by 28
“Guidelines have recommended these therapies for reducing the risk of cardiovascular events in those with DM who also have CVD or multiple risk factors [13, 14].”
BackgroundLiu, S., Liu, J., Si, L., Ke, X., Liu, L., Ren, Y., Bao, S., Li, F., Yu, Y., Pan, Q., et al. (2023) · BMJ Global Health · doi:10.1136/bmjgh-2022-010942 · Cited by 25
Sun, M., Liu, F., Yan, P., Chen, W., & Wang, X. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17906 · Cited by 27
Posttransplant diabetes mellitus: recent developments in pharmacological management of hyperglycemia
Munoz Pena, J. M., & Cusi, K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad395 · Cited by 24
Zhu, J., Zhou, Y., Li, Q., & Wang, G. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02612-z · Cited by 26
Butucă, A., Dobrea, C. M., Arseniu, A. M., Frum, A., Chiş, A. A., Rus, L. L., Ghibu, S., Juncan, A. M., Muntean, A. C., Lazăr, A. E., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12051124 · Cited by 31
“Depending on glycemic status, the glucagon secretion could be increased in normoglycemic or hypoglycemic patients (glucagonotropic effect) or inhibited in hyperglycemic patients (glucagonostatic effect) [22,32,33].”
BackgroundPetchsila, K., Prueksaritanond, N., Insin, P., Yanaranop, M., & Chotikawichean, N. (2020) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2020.21.3.733 · Cited by 24
Goldenberg, R. M., Ahooja, V., Clemens, K. K., Gilbert, J. D., Poddar, M., & Verma, S. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.09.005 · Cited by 23
Cost and utilization of healthcare services for persons with diabetes
Reynolds, E. L., Mizokami‐Stout, K., Putnam, N. M., Banerjee, M., Albright, D. K., Ang, L. P., Lee, J. M., Pop‐Busui, R., Feldman, E. L., & Callaghan, B. C. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110983 · Cited by 25
Shrestha, D. B., Budhathoki, P., Sedhai, Y. R., Karki, P., Gurung, S., Raut, S. R., Damonte, J. I., Buono, M. G. D., Mojadidi, M. K., Elgendy, I. Y., et al. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001099 · Cited by 26
New Hypoglycemic Drugs: Combination Drugs and Targets Discovery
Ni, X., Zhang, L., Feng, X., & Tang, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.877797 · Cited by 27
Circadian secretion rhythm of GLP-1 and its influencing factors
Liu, C., Liu, Y., Xin, Y., & Wang, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.991397 · Cited by 24
Zhan, J., Jin, K., Ding, N., Zhou, Y., Guo, H., Yuan, S., Xie, R., Zheng, W., Chen, C., Li, H., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.12.009 · Cited by 24
Peng, Z., Yang, C., Kuo, S., Wu, C., Lin, W., & Ou, H. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.46928 · Cited by 23
Caring for Patients With Diabetes in Stroke Neurology
Kernan, W. N., Forman, R., & Inzucchi, S. E. (2022) · Stroke · doi:10.1161/strokeaha.122.038163 · Cited by 26
Lawrence, S. E., Chandran, M. M., Park, J. M., Sweiss, H., Jensen, T. B., Choksi, P. U., & Crowther, B. R. (2023) · Clinical Transplantation · doi:10.1111/ctr.14922 · Cited by 23
Lui, D. T. W., Tang, E. H. M., Wu, T., Au, I. C. H., Lee, C., Woo, Y. C., Tan, K. C. B., & Wong, C. K. H. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01772-0 · Cited by 25
Metadata
- Authors
- American Diabetes Association Professional Practice Committee
- Corresponding author
- American Diabetes Association Professional Practice Committee
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2021-12-16
- Volume
- 45
- Issue
- Supplement_1
- Pages
- S125-S143
- ISSN
- 0149-5992 (ISSN-L)
- OpenAlex
- W4200161106
- Cited by
- 1,555
- References
- 106
- Citations by year
- 2026: 42 · 2025: 132 · 2024: 219 · 2023: 393 · 2022: 403 · 2021: 153
- FWCI
- 44.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.